Crackdown on Codeine Cough Syrup Mafia: UP Authorities Seal Firms, Expose Gujarat-Lucknow Nexus

Lucknow– In a sweeping enforcement drive, Uttar Pradesh’s Food Safety and Drug Administration (FSDA) has dismantled a sprawling illegal network peddling codeine-laced cough syrups as intoxicants, unearthing a mafia-style syndicate with roots in Gujarat. Prompted by intelligence on unauthorized bulk supplies, FSDA teams raided multiple pharmaceutical firms across Lucknow, Sitapur, and Raebareli, sealing at least one medical store and seizing incriminating records that reveal a cross-state supply chain fueling widespread substance abuse.
The operation, launched on a recent Sunday under the iron-fisted directives of IAS Commissioner Roshan Jacob, targeted 10 major entities suspected of hoarding and distributing narcotic drugs disguised as legitimate cough remedies. “No firm or individual involved in the illegal sale of narcotic drugs will be spared,” FSDA officials declared, underscoring a zero-tolerance stance as raids exposed falsified records, unsatisfactory storage practices, and bulk sales to shadowy buyers.

The crackdown has sent shockwaves through the pharmaceutical trade, with several operators fleeing their premises and locals reporting abandoned warehouses in anticipation of inspections.
Led by Assistant Commissioner (Drugs) Brijesh Kumar and a 13-member team of inspectors from across districts, the raids zeroed in on Lucknow’s Transport Nagar—a notorious hub for drug storage. At M/s Idhika Lifesciences and M/s Aarpik Pharmaceuticals Pvt. Ltd., investigators uncovered evidence of large-scale tampering: entire lots of codeine syrups were funneled to single parties for illicit resale across Uttar Pradesh’s 13 districts, including Sitapur and Raebareli. Documents seized painted a picture of systemic evasion, with firms purchasing thousands of bottles only to underreport sales and skirt regulations.
The most dramatic action unfolded in Sitapur, where M/s Naimis Dham Medical Store was sealed on the spot after discrepancies emerged—records showed 2,600 bottles procured from Idhika Lifesciences, but only 1,000 were accounted for on-site. Local police were immediately looped in for potential criminal probes. Nearby, M/s Novon Lifesciences in Transport Nagar stood eerily vacant; its proprietor, reached by phone, confessed to holding codeine stock and vowed to surrender bills within 24 hours, though skepticism lingers amid the firm’s sudden disappearance.
Further probes linked the network to a web of complicit players: M/s Shubhash Medical Agency in Lucknow’s Rajajipuram allegedly supplied syrups to M/s Balaji Medical Store, which in turn offloaded them to M/s Shyam Medical Agency—a firm already stripped of its license, with its operator behind bars for prior narcotic violations. Other implicated entities include M/s MJS Agencies Pvt. Ltd., M/s Reliance Pharmaceuticals, M/s Medrate Pharmaceuticals, and M/s Palas Pharmaceutical Pvt. Ltd. (whose license hangs in suspension). At the helm? Manohar Jaiswal, the Gujarat-based owner of Idhika and Aarpik, who remotely orchestrated shipments from manufacturing units in the western state, turning cough syrup into a lucrative black-market “alcohol” alternative.
Codeine cough syrups, intended for legitimate respiratory relief, have morphed into a public health crisis in Uttar Pradesh, often mixed with sodas or sold straight to addicts seeking a cheap high. This mafia, thriving on lax oversight, exploits bulk manufacturing in Gujarat to flood Lucknow’s warehouses before fanning out to rural districts. “Actions to curb the illegal trade of narcotic drugs will continue,” affirmed departmental sources, signaling relentless follow-ups that could cascade into license cancellations, arrests, and interstate coordination with Gujarat authorities.

Commissioner Jacob’s proactive role—sparked by tip-offs on the syndicate’s operations—has been hailed as a turning point, with the FSDA vowing to expand scrutiny to all 13 affected districts. As operators scatter and records unravel, this raid not only disrupts a multimillion-rupee racket but also spotlights the urgent need for tighter cross-border regulations to stem the flow of addictive substances masquerading as medicine.
Public health experts warn that unchecked proliferation risks a surge in addiction and overdose cases, urging pharmacies statewide to double-check suppliers. For now, Lucknow’s underbelly feels the heat, but the FSDA’s message is clear: the cough syrup mafia’s days are numbered.
  • Related Posts

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    New Delhi: AstraZeneca’s India-arm has partnered with National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging geographies in a bid to extend…

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

    ‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

    ‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

    Governments have moved for Price Transparency in Hospitals to help patients cope with bills

    Governments have moved for Price Transparency in Hospitals to help patients cope with bills

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction